glp 1 agonist chart Overview of GLP-1 Receptor Agonists Available in the United States for Updated Ranking and Side Effects
Description
The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer
Neurodegenerative diseases, including Alzheimers Disease (AD) and Parkinsons Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system
Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells
Berberine and GLP-1 are fundamentally different compounds targeting distinct metabolic pathways
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide
